Developer docs
API playgroundTry for free, no card

Search company profiles

LucasPye BIO

Full company profile

uuid0000js3

Namestring
LucasPye BIO
Websiteurl
lucaspyebio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

LucasPye BIO is a privately-held Contract Development and Manufacturing Organization (CDMO) founded in 2018 and headquartered in Philadelphia, Pennsylvania. The company manufactures protein-therapeutic and viral-therapeutic drug products, placing it in the specialized biologics contract manufacturing segment of the pharmaceutical services industry. Its target customers are biopharmaceutical developers requiring contract production capacity for biologic and viral-based drug substances, including emerging gene therapy and protein-based therapeutic developers.

Operating with a small team of 11-50 employees, LucasPye BIO positions itself as a specialized service provider in an industry where cGMP-compliant biologics manufacturing capabilities are technically demanding and capital-intensive. The company's business model follows the standard CDMO fee-for-service structure, generating revenue through development and manufacturing contracts with biologic drug developers, though no specific pricing models, contract values, or customer relationships are disclosed in the source data.

The company is founder-led, with Tia Lyles-Williams serving as CEO and founder. Capital formation to date has been limited, with a single documented funding round of $1,000,000 raised in May 2019 from undisclosed investors. The absence of subsequent funding rounds, detailed product disclosures, customer references, or partnerships in the source data indicates that LucasPye BIO remains at an early operational stage relative to scaled CDMO competitors.

Short descriptiontext

LucasPye BIO is a Philadelphia-based contract development and manufacturing organization (CDMO) that produces protein-therapeutic and viral-therapeutic drug products for biopharmaceutical clients. Founded in 2018, the privately-held company operates with 11-50 employees under founder and CEO Tia Lyles-Williams.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopharmaceutical CDMO services, protein therapeutic manufacturing, viral therapeutic manufacturing, contract development services, biologics drug product manufacturing
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical CDMO Services
Social media profiles3 records
Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LucasPye BIO is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures protein-therapeutic and viral-therapeutic drug products on behalf of biopharmaceutical clients. The company delivers outsourced development and manufacturing services for biologic drug substances and drug products within its Philadelphia-based operations.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Protein-Therapeutic Drug Product CDMO Services
CategoryBiologics Contract Manufacturing
Description

Contract development and manufacturing services for protein-based therapeutic drug products, delivered by LucasPye BIO to biopharmaceutical clients requiring outsourced biologics capacity.

2Viral-Therapeutic Drug Product CDMO Services
CategoryBiologics Contract Manufacturing
Description

Contract development and manufacturing services for viral-based therapeutic drug products, addressing sponsors needing specialized viral-therapeutic process and production capability.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Global CDMO offering mammalian biologics and viral-vector manufacturing services across development and commercial scales. Directly competes with LucasPye BIO across protein therapeutics and gene-therapy drug substance manufacturing.

TypeDirect peer
Description

Biopharma manufacturing company focused on biologics, viral vectors, and cell therapies with modern GMP capacity. Competes with LucasPye BIO for emerging biotech sponsors seeking outsourced protein and viral-therapeutic manufacturing.

TypeDirect peer
Description

Specialized CDMO focused on viral vectors, viral vaccines, and viral-vector drug product manufacturing. Closely comparable to LucasPye BIO's viral-therapeutic drug product offering.

4Cobra Biologics (Charles River Laboratories)
TypeDirect peer
Description

CDMO offering plasmid DNA, viral vector, and biologics development and manufacturing services. Direct competitor in the protein-therapeutic and viral-therapeutic CDMO space.

TypeBroad incumbent
Description

Large-scale global CDMO with deep biologics and viral-vector capabilities across drug substance and drug product. Overlaps with LucasPye BIO across protein and viral-therapeutic manufacturing, though at vastly greater scale.

TypeBroad incumbent
Description

World-leading CDMO with extensive mammalian and microbial biologics manufacturing services. Indirectly competes with LucasPye BIO for protein-therapeutic CDMO programs while serving much larger commercial sponsors.

TypeBroad incumbent
Description

Global biologics CDMO with end-to-end discovery, development, and manufacturing services. Operates in the same protein-therapeutic manufacturing category as LucasPye BIO at substantially greater scale.

TypeDirect peer
Description

Specialty CDMO focused on viral vector and gene therapy manufacturing with clinical and commercial GMP capacity. Closely comparable to LucasPye BIO's viral-therapeutic drug product offering for cell and gene therapy sponsors.

TypeDirect peer
Description

CDMO offering biologics and microbial fermentation services including plasmid and protein therapeutics. Comparable CDMO scale and modality mix to LucasPye BIO.

TypeBroad incumbent
Description

Diversified life sciences and CDMO services organization with biologics drug substance and drug product capabilities. Broad incumbent competing for outsourced protein-therapeutic manufacturing programs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LucasPye BIO

Biopharmaceutical CDMO Serviceslucaspyebio.com

LucasPye BIO is a Philadelphia-based contract development and manufacturing organization (CDMO) that produces protein-therapeutic and viral-therapeutic drug products for biopharmaceutical clients. Founded in 2018, the privately-held company operates with 11-50 employees under founder and CEO Tia Lyles-Williams.

What LucasPye BIO does

LucasPye BIO is a privately-held Contract Development and Manufacturing Organization (CDMO) founded in 2018 and headquartered in Philadelphia, Pennsylvania. The company manufactures protein-therapeutic and viral-therapeutic drug products, placing it in the specialized biologics contract manufacturing segment of the pharmaceutical services industry. Its target customers are biopharmaceutical developers requiring contract production capacity for biologic and viral-based drug substances, including emerging gene therapy and protein-based therapeutic developers.

Operating with a small team of 11-50 employees, LucasPye BIO positions itself as a specialized service provider in an industry where cGMP-compliant biologics manufacturing capabilities are technically demanding and capital-intensive. The company's business model follows the standard CDMO fee-for-service structure, generating revenue through development and manufacturing contracts with biologic drug developers, though no specific pricing models, contract values, or customer relationships are disclosed in the source data.

The company is founder-led, with Tia Lyles-Williams serving as CEO and founder. Capital formation to date has been limited, with a single documented funding round of $1,000,000 raised in May 2019 from undisclosed investors. The absence of subsequent funding rounds, detailed product disclosures, customer references, or partnerships in the source data indicates that LucasPye BIO remains at an early operational stage relative to scaled CDMO competitors.

LucasPye BIO firmographics

Firmographics
Name
LucasPye BIO
Website
https://lucaspyebio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
LucasPye BIO is a Philadelphia-based contract development and manufacturing organization (CDMO) that produces protein-therapeutic and viral-therapeutic drug products for biopharmaceutical clients. Founded in 2018, the privately-held company operates with 11-50 employees under founder and CEO Tia Lyles-Williams.
Ownership category
akta.pro rank

LucasPye BIO industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Biopharmaceutical CDMO services
  • Protein therapeutic manufacturing
  • Viral therapeutic manufacturing
  • Contract development services
  • Biologics drug product manufacturing

Where LucasPye BIO is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Markets served

LucasPye BIO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

LucasPye BIO product offering

Product offering

Core offering

LucasPye BIO is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures protein-therapeutic and viral-therapeutic drug products on behalf of biopharmaceutical clients. The company delivers outsourced development and manufacturing services for biologic drug substances and drug products within its Philadelphia-based operations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Protein-Therapeutic Drug Product CDMO Services Contract development and manufacturing services for protein-based therapeutic drug products, delivered by LucasPye BIO to biopharmaceutical clients requiring outsourced biologics capacity.
  • Viral-Therapeutic Drug Product CDMO Services Contract development and manufacturing services for viral-based therapeutic drug products, addressing sponsors needing specialized viral-therapeutic process and production capability.

Companies that use LucasPye BIO

Customer profile

Ideal customer profiles1 record

LucasPye BIO technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LucasPye BIO partnerships and signals

Strategic signal

Recent moves3 records

LucasPye BIO competitors and assessment

Company assessment

Direct peers

  • AGC Biologics: Global CDMO offering mammalian biologics and viral-vector manufacturing services across development and commercial scales. Directly competes with LucasPye BIO across protein therapeutics and gene-therapy drug substance manufacturing.
  • Resilience: Biopharma manufacturing company focused on biologics, viral vectors, and cell therapies with modern GMP capacity. Competes with LucasPye BIO for emerging biotech sponsors seeking outsourced protein and viral-therapeutic manufacturing.
  • Vibalogics: Specialized CDMO focused on viral vectors, viral vaccines, and viral-vector drug product manufacturing. Closely comparable to LucasPye BIO's viral-therapeutic drug product offering.
  • Cobra Biologics (Charles River Laboratories): CDMO offering plasmid DNA, viral vector, and biologics development and manufacturing services. Direct competitor in the protein-therapeutic and viral-therapeutic CDMO space.
  • Andelyn Biosciences: Specialty CDMO focused on viral vector and gene therapy manufacturing with clinical and commercial GMP capacity. Closely comparable to LucasPye BIO's viral-therapeutic drug product offering for cell and gene therapy sponsors.
  • BioVectra: CDMO offering biologics and microbial fermentation services including plasmid and protein therapeutics. Comparable CDMO scale and modality mix to LucasPye BIO.

Broad incumbents

  • Catalent: Large-scale global CDMO with deep biologics and viral-vector capabilities across drug substance and drug product. Overlaps with LucasPye BIO across protein and viral-therapeutic manufacturing, though at vastly greater scale.
  • Lonza Biologics: World-leading CDMO with extensive mammalian and microbial biologics manufacturing services. Indirectly competes with LucasPye BIO for protein-therapeutic CDMO programs while serving much larger commercial sponsors.
  • WuXi Biologics: Global biologics CDMO with end-to-end discovery, development, and manufacturing services. Operates in the same protein-therapeutic manufacturing category as LucasPye BIO at substantially greater scale.
  • Thermo Fisher Scientific (Patheon CDMO): Diversified life sciences and CDMO services organization with biologics drug substance and drug product capabilities. Broad incumbent competing for outsourced protein-therapeutic manufacturing programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

LucasPye BIO social profiles

Digital presence

LucasPye BIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LucasPye BIO leadership team

Management profile

Number of profiles

Profiles1 record

LucasPye BIO funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LucasPye BIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LucasPye BIO

What does LucasPye BIO do?

LucasPye BIO is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures protein-therapeutic and viral-therapeutic drug products on behalf of biopharmaceutical clients. The company delivers outsourced development and manufacturing services for biologic drug substances and drug products within its Philadelphia-based operations.

Is LucasPye BIO a public or private company?

LucasPye BIO is a private company. It is classified as venture growth investor backed and is currently operating.

When was LucasPye BIO founded?

LucasPye BIO was founded in 2018. It employs 11 to 50 people.

Where is LucasPye BIO based?

LucasPye BIO is headquartered in Philadelphia, United States, in the North America region.

Who are LucasPye BIO's main competitors?

Direct peers on record are AGC Biologics, Resilience, Vibalogics, Cobra Biologics (Charles River Laboratories), Andelyn Biosciences and BioVectra. Broad incumbents are Catalent, Lonza Biologics, WuXi Biologics and Thermo Fisher Scientific (Patheon CDMO).

Does LucasPye BIO have an API?

No public API is recorded for LucasPye BIO.

What industry is LucasPye BIO in?

LucasPye BIO's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals